Acessa Health touts data from 10-year review of uterine fibroid treatment

Acessa Health today touted data from a 10-year systematic review and meta-analysis of its Acessa system designed to treat uterine fibroids and comparable procedures, touting reduced blood loss, hospitalization time and readmission rates.

Data from the 10-year review was presented at the MIS Week 2017 conference by Dr. Yelena Havryliuk of Weill Cornell Medical College.

The review included assessments of 143 journal articles from between 2006 and 2016 and a quantitative synthesis of 45 studies during that time, Austin, Texas-based Acessa Health said.

“I have used the Acessa System and been impressed with minimal blood loss, quick recovery, low re-intervention rates, and resolution of symptoms expressed by my patients,” Dr. Havryliuk said in a prepared statement.

In the analysis, researchers compared weighted combined results from hysterectomy trials with those from uterine-preserving firbroid studies including myomectomy, uterine artery embolization, magnetic resonance-guided focused ultrasound and laparoscopic radiofrequency ablation using the Acessa system.

Results indicated a mean blood loss following procedures using Accessa’s laparoscopic RF ablation tech of 35 mL, nearly 8 times lower than the 269 mL and 175 mL reported with hysterectomy and myomectomy procedures.

Procedures performed with the Acessa system were done as outpatient procedures, the company said, eliminating the average 2 to 2.4 day hospital stay associated with other procedures. Reinterventions were also lower with the Acessa, at 4.2% at 27-35 months, versus rates of 14.8% to 30.5% at 13-14 months for uterine artery embolization and MR-guided focused ultrasound procedures.

Acessa said that readmission rates were at 0.7% for patients treated with its system, versus 7.4% for MR-guided focused ultrasound, 3.4% for uterine artery embolization and 2.7% for myomectomy procedures.

“The Acessa team is thrilled with the results of this comprehensive data review that overwhelmingly supports our technology as a superior intervention for women with symptomatic fibroids. Acessa has been featured in more than 20 peer reviewed studies supporting its use. Dr. Harvryliuk’s meta review provides yet another encouraging data point as we seek to redefine the standard of care for millions of women suffering from fibroids,” CEO Kim Rodriguez said in a press release.

In June, Halt Medical was sold to Acessa Health in a bankruptcy buyout, after which Acessa proceeded to raise $30 million in a Series A funding round.